Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Richard Greene

Physician Assistant, Medical Murray, KY Physician Assistant

NPI 1982739199 CMS profile 10925482

300 S 8Th St Ste 509E, Murray, KY 42071

Open in the dashboard

General payments

$5,665

332 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Richard Greene of Murray, KY is reported in the CMS Open Payments database as having received $5,665 across 332 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,181 63
2024 General $1,373 71
2023 General $1,123 69
2022 General $832 54
2021 General $1,156 75

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Greene
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Richard Greene were reported at $1,181. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Richard Greene Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,156 $156 $41–$563 $132
2022 $832 $185 $55–$649 $149
2023 $1,123 $199 $58–$717 $160
2024 $1,373 $206 $62–$740 $164
2025 $1,181 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,153 79 payments
  2. Janssen Biotech, Inc. $1,112 54 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $982 55 payments
  4. AbbVie, Inc. $521 38 payments
  5. Pfizer Inc. $348 17 payments
  6. Gilead Sciences, Inc. $234 15 payments
  7. Madrigal Pharmaceuticals $231 13 payments
  8. Phathom Pharmaceuticals, Inc. $186 12 payments
  9. QOL Medical, LLC $158 10 payments
  10. Genzyme Corporation $152 8 payments
  11. Other $588 31 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,389 327 payments
  2. Education $276 5 payments
Products named General payments · program years 2021–2025
  1. ENTYVIO $879 48 payments
  2. STELARA $807 37 payments
  3. XIFAXAN $733 50 payments
  4. TRULANCE $419 29 payments
  5. TREMFYA $350 18 payments
  6. XELJANZ $348 17 payments
  7. VELSIPITY $283 14 payments
  8. HUMIRA $248 19 payments
  9. SIMPONI ARIA $198 14 payments
  10. REMICADE $198 14 payments
  11. Other $1,883 115 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

2,691

Median for Physician Assistant: 241

Drug cost

$907,348

Median for Physician Assistant: $4,110

Branded share of claims

17.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 32 $398,021
Entyvio Vedolizumab Brand 18 $144,621
Xifaxan Rifaximin Brand 39 $121,023
Creon Lipase/Protease/Amylase Brand 33 $79,659
Linzess Linaclotide Brand 67 $41,528
Trulance Plecanatide Brand 17 $18,606
Pentasa Mesalamine Brand 16 $18,372
Omeprazole Generic 699 $9,849
Esomeprazole Magnesium Generic 80 $8,770
Bethanechol Chloride Generic 90 $7,770

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$44,177

Medicare's payments for the services billed

Medicare patients

433

Average age 72

Services billed

960

263 women, 170 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Diabetes 30%
Depression 30%
Ischemic heart disease 28%
Chronic kidney disease 27%
COPD 21%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
STELARA
  • Janssen Biotech, Inc. $261
$261 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $202
$202 18 —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $126
$126 39 —
VELSIPITY
  • PFIZER INC. $78
$78 — —
XELJANZ
  • PFIZER INC. $78
$78 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

332 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record